drugset / Trial / NCT00648726

An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia

NCT00648726

Phase 3 Completed 139 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To validate the efficacy and safety of azithromycin for the treatment of Chinese patients hospitalized with community-acquired pneumonia (CAP), compared with cefuroxime or the combination of cefuroxime plus oral erythromycin.

Timeline

Start
2003-01
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 500 mg Intravenous
Comparator Cefuroxime Small molecule 0.5 g Intravenous
Comparator Erythromycin Small molecule 0.5 g Oral

Indications